Skip to main content
Equibles

Prosight Management, LP

Position in ZYME — Zymeworks Inc.

CIK 1617201 DALLAS, TX
Back to ZYME Full portfolio

Position in ZYME

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$17,629,704
+$4,131,918 QoQ
Shares Held
674,434
+25.1% QoQ
Ownership
0.950%
of shares outstanding
% of Portfolio
3.04%
of 13F equity value
Holder Rank
#17
of 202 holders
Holding Since
Sep 2023
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ZYME Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Prosight Management, LP holds $415,390,745 across 22 Biotechnology names. ZYME ranks #9 (4.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LKFT
Lakefront Biotherapeutics NV
 2,043,344 $61,259,453
2 JANX
Janux Therapeutics, Inc.
 3,804,481 $58,436,828
3 NKTR
Nektar Therapeutics
 810,000 $56,546,100
4 STTK
Shattuck Labs, Inc.
 5,957,877 $41,347,666
5 INSM
INSMED Inc
 375,609 $40,047,431
6 ALNY
Alnylam Pharmaceuticals, Inc.
 98,080 $29,525,022
7 SNDX
Syndax Pharmaceuticals Inc
 1,200,000 $26,232,000
8 KURA
Kura Oncology, Inc.
 2,021,964 $22,180,945

All Filings in ZYME

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $17,629,704 674,434
2026-03-31 $13,497,786 539,049
2025-12-31 $13,965,247 530,393
2025-09-30 $12,803,355 749,611
2025-06-30 $16,439,295 1,309,904
2025-03-31 $11,400,597 957,229
2024-12-31 $12,004,800 820,000
2024-09-30 $11,515,867 917,599
2024-06-30 $10,041,800 1,180,000
2024-03-31 $4,323,172 410,948
2023-09-30 $674,607 106,405